Corbus Pharmaceuticals Holdings Inc. reported that its sole candidate – resunab – added to standard-of-care (SOC) immunosuppressive drugs, out-performed a placebo with SOC during a phase II trial in patients with diffuse cutaneous systemic sclerosis, an autoimmune disorder.